৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Type 2 Diabetes Mellitus
Adjunct to diet and exercise to improve glycemic control in adults
Subcutaneous (SC) injection: abdomen, thigh, or upper arm
Administer once weekly, same day each week, any time of day, with or without meals
Weekly administration day can be changed if ≥48 hours between doses
Rotate injection sites within the same body region
Start: 0.25 mg SC weekly for 4 weeks
Then: increase to 0.5 mg SC weekly
If inadequate glycemic control after ≥4 weeks on 0.5 mg, increase to 1 mg SC weekly
Hepatic impairment: No adjustment required
<18 years: Safety and efficacy not established
Renal impairment: No adjustment required
Personal/family history of medullary thyroid carcinoma (MTC)
Patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Known hypersensitivity to semaglutide or product components
GLP-1 receptor agonist
Enhances glucose-dependent insulin secretion
Suppresses inappropriate glucagon secretion
Slows gastric emptying
Monitor for hypoglycemia when combined with insulin or sulfonylureas
Use caution with oral medications due to delayed gastric emptying
>10%
Nausea (15.8–20.3%)
Symptomatic hypoglycemia (16.7–29.8% adjunctive; 8.3–10.7% severe)
1–10%
Vomiting (5–9.2%)
Diarrhea (8.5–8.8%)
Abdominal pain (5.7–7.3%)
Constipation (3.1–5%)
Dyspepsia (2.7–3.5%)
Eructation (1.1–2.7%)
Hypoglycemia (1.6–3.8% monotherapy)
Flatulence (0.4–1.5%)
GERD (1.5–1.9%)
<1%
Gastritis (0.4–0.8%)
Cholelithiasis (0.4%)
Fatigue, dysgeusia, dizziness (>0.4%)
Injection site reaction (0.2%)
Pregnancy: Limited human data; animal studies suggest fetal risk
Discontinue ≥2 months before planned pregnancy (long washout period)
Poorly controlled diabetes increases maternal/fetal risks (DKA, preeclampsia, stillbirth, macrosomia)
Lactation: No human data; detected in rat milk at lower levels than plasma
With insulin or sulfonylureas → ↑ risk of hypoglycemia (dose adjustment may be needed)
Delays gastric emptying → may affect absorption of oral medications



Indication: Type 2 Diabetes Mellitus
Administration: Subcutaneous (SC) injection — administer to abdomen, thigh, or upper arm. Inject once weekly, on the same day each week, at any time of day, with or without meals. The day of weekly administration may be changed if necessary, provided at least 48 hours have passed between doses. Use a different injection site each week when injecting in the same body region.
Adult Dose: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Start with 0.25 mg SC weekly for 4 weeks, then increase to 0.5 mg weekly. If glycemic control is not achieved after ≥ 4 weeks on 0.5 mg, increase to 1 mg weekly. No dosage adjustment required for hepatic impairment.
Child Dose: Safety and efficacy not established (< 18 years).
Renal Dose: No dosage adjustment required for renal impairment.
Contraindication: Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.
Mode of Action: Glucagon‑like peptide‑1 (GLP‑1) agonist. Enhances glucose‑dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.
Precaution: Use with caution in patients with a history of pancreatitis or severe gastrointestinal disease.
Side Effects: Common (> 10%): Nausea, symptomatic hypoglycemia. Occasional (1–10%): Vomiting, diarrhea, abdominal pain, constipation, dyspepsia, eructation, flatulence, GERD. Rare (< 1%): Gastritis, cholelithiasis, fatigue, dizziness, injection‑site reaction.
Pregnancy & Lactation: Limited data in pregnant women. Potential fetal risk based on animal studies — discontinue at least 2 months before planned pregnancy.
N/A




